Two Chinese pharma companies, which supplied 5.5 lakh rapid testing kits for COVID-19 to India, said they are ready to cooperate with Indian agencies looking into allegations of poor accuracy of their products.
In separate statements, Guongzhou Wondfo Biotech and Livzon Diagnostics said they follow strict quality control of their products, asserting that specified guidelines must be followed in storage of the kits as as well in their usages to get accurate results.
India's apex medical research body ICMR on Tuesday advised states to stop using the rapid antibody test kits for next two days till it examines their quality following complaints that they are not fully effective in detecting coronavirus infection.
Last week, India procured 5.5 lakh rapid antibody test kits from these two Chinese firms and they were distributed to several states reporting rising cases of coronavirus infection.
While Guongzhou Wondfo Biotech supplied 3 lakh test kits, Livzon Diagnostics delivered 2.5 lakh.
Livzon Diagnostics, in its statement said: "We are shocked to receive negative reports from India related to poor accuracy of COVID 19 rapid testing kits made in China including our brand. We have shown great concern on this issue, and we are willing to coordinate with the related government departments for investigation."
Disclaimer: No Business Standard Journalist was involved in creation of this content